

Huntington Potter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4335549/publications.pdf>

Version: 2024-02-01

56
papers

5,095
citations

304743

22
h-index

233421

45
g-index

67
all docs

67
docs citations

67
times ranked

7875
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. <i>Nature Genetics</i> , 2019, 51, 414-430.	21.4	1,962
2	Amyloid-associated proteins β 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β -protein into filaments. <i>Nature</i> , 1994, 372, 92-94.	27.8	909
3	Rare coding variants in PLCC2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. <i>Nature Genetics</i> , 2017, 49, 1373-1384.	21.4	783
4	Down syndrome and Alzheimer's disease: Common pathways, common goals. <i>Alzheimer's and Dementia</i> , 2015, 11, 700-709.	0.8	218
5	Alzheimer A β neurotoxicity: Promotion by antichymotrypsin, ApoE4; inhibition by A β -related peptides. <i>Neurobiology of Aging</i> , 1996, 17, 773-780.	3.1	105
6	GM-CSF Upregulated in Rheumatoid Arthritis Reverses Cognitive Impairment and Amyloidosis in Alzheimer Mice. <i>Journal of Alzheimer's Disease</i> , 2010, 21, 507-518.	2.6	101
7	Exosome Isolation by Ultracentrifugation and Precipitation and Techniques for Downstream Analyses. <i>Current Protocols in Cell Biology</i> , 2020, 88, e110.	2.3	100
8	The inflammation-induced pathological chaperones ACT and apo-E are necessary catalysts of Alzheimer amyloid formation. <i>Neurobiology of Aging</i> , 2001, 22, 923-930.	3.1	79
9	Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-9.	2.0	67
10	Exosomal biomarkers in Down syndrome and Alzheimer's disease. <i>Free Radical Biology and Medicine</i> , 2018, 114, 110-121.	2.9	64
11	Transfection by Electroporation. <i>Current Protocols in Molecular Biology</i> , 2003, 62, Unit 9.3.	2.9	52
12	Further understanding the connection between Alzheimer's disease and Down syndrome. <i>Alzheimer's and Dementia</i> , 2020, 16, 1065-1077.	0.8	52
13	Transfection by Electroporation. <i>Current Protocols in Molecular Biology</i> , 2018, 121, 9.3.1-9.3.13.	2.9	50
14	Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12158.	3.7	44
15	Identification of a Chymotrypsin-Like Mast Cell Protease in Rat Brain Capable of Generating the N-Terminus of the Alzheimer Amyloid β -Protein. <i>Journal of Neurochemistry</i> , 1993, 61, 567-577.	3.9	41
16	Alzheimer's Disease: Recent Advances in Understanding the Brain Amyloid Deposits. <i>Nature Biotechnology</i> , 1989, 7, 147-153.	17.5	36
17	Mitotic defects lead to neuronal aneuploidy and apoptosis in frontotemporal lobar degeneration caused by MAPT mutations. <i>Molecular Biology of the Cell</i> , 2018, 29, 575-586.	2.1	36
18	Alzheimer amyloid beta inhibition of Eg5/kinesin 5 reduces neurotrophin and/or transmitter receptor function. <i>Neurobiology of Aging</i> , 2014, 35, 1839-1849.	3.1	35

#	ARTICLE	IF	CITATIONS
19	The Protease Inhibitor, α 1-Antichymotrypsin, Is a Component of the Brain Amyloid Deposits in Normal Aging and Alzheimer's Disease. <i>Annals of Medicine</i> , 1989, 21, 77-81.	3.8	33
20	Chromosome Instability and Mosaic Aneuploidy in Neurodegenerative and Neurodevelopmental Disorders. <i>Frontiers in Genetics</i> , 2019, 10, 1092.	2.3	32
21	Astrogliosis and episodic memory in late life: higher GFAP is related to worse memory and white matter microstructure in healthy aging and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 103, 68-77.	3.1	31
22	The essential role of inflammation and induced gene expression in the pathogenic pathway of Alzheimer's disease. <i>Frontiers in Bioscience - Landmark</i> , 1998, 3, d436-446.	3.0	25
23	Varicella-Zoster Virus Infection of Primary Human Spinal Astrocytes Produces Intracellular Amylin, Amyloid- β , and an Amyloidogenic Extracellular Environment. <i>Journal of Infectious Diseases</i> , 2020, 221, 1088-1097.	4.0	25
24	Mild behavioral impairment as a predictor of cognitive functioning in older adults. <i>International Psychogeriatrics</i> , 2021, 33, 285-293.	1.0	25
25	Inhibition of the Motor Protein Eg5/Kinesin-5 in Amyloid β -Mediated Impairment of Hippocampal Long-Term Potentiation and Dendritic Spine Loss. <i>Molecular Pharmacology</i> , 2016, 89, 552-559.	2.3	22
26	Granulocyte Macrophage Colony Stimulating Factor Treatment is Associated with Improved Cognition in Cancer Patients. <i>Brain Disorders & Therapy</i> , 2012, 01, .	0.1	19
27	Innate Immune System Activation and Neuroinflammation in Down Syndrome and Neurodegeneration: Therapeutic Targets or Partners?. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 718426.	3.4	17
28	The innate immune system stimulating cytokine GM-CSF improves learning/memory and interneuron and astrocyte brain pathology in Dp16 Down syndrome mice and improves learning/memory in wild-type mice. <i>Neurobiology of Disease</i> , 2022, 168, 105694.	4.4	11
29	USE OF FUSED CIRCULATIONS TO INVESTIGATE THE ROLE OF APOLIPOPROTEIN E AS AMYLOID CATALYST AND PERIPHERAL SINK IN ALZHEIMER'S DISEASE. <i>Technology and Innovation</i> , 2012, 14, 199-208.	0.2	10
30	Transfection by Electroporation. <i>Current Protocols in Immunology</i> , 2017, 117, 10.15.1-10.15.9.	3.6	10
31	Amylin, $A\beta$ 42, and Amyloid in Varicella Zoster Virus Vasculopathy Cerebrospinal Fluid and Infected Vascular Cells. <i>Journal of Infectious Diseases</i> , 2021, 223, 1284-1294.	4.0	10
32	Acute zoster plasma contains elevated amyloid, correlating with $A\beta$ 42 and amylin levels, and is amyloidogenic. <i>Journal of NeuroVirology</i> , 2020, 26, 422-428.	2.1	9
33	Recruiting the innate immune system with GM-CSF to fight viral diseases, including West Nile Virus encephalitis and COVID-19. <i>F1000Research</i> , 2020, 9, 345.	1.6	8
34	Transfection by Electroporation. <i>Current Protocols in Neuroscience</i> , 1997, 1, A.1E.1-A.1E.5.	2.6	4
35	[P4â€“572]: INTERIM REPORT OF A PHASE 2 PILOT SAFETY AND EFFICACY TRIAL OF GMâ€“CSF/LEUKINE [®] IN MILDâ€“TOâ€“MODERATE ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 0.8 2017, 13, P1572.		4
36	Transfection by Electroporation. <i>Current Protocols in Immunology</i> , 1992, 3, Unit 10.15.	3.6	2

#	ARTICLE	IF	CITATIONS
37	Transfection by Electroporation. Current Protocols in Cell Biology, 2003, 19, Unit 20.5.	2.3	2
38	Targeting the Interaction Between Apolipoprotein E and Amyloid Precursor Protein: A Novel Alzheimer's Disease Therapy. Biological Psychiatry, 2019, 86, 169-170.	1.3	2
39	David H. Dressler 1941-2014. Nature Genetics, 2014, 46, 1044-1044.	21.4	1
40	[P3-141]: FOLATE PREVENTS THE DETRIMENTAL EFFECTS OF OLIGOMERIC A β ON INSULIN RECEPTOR LOCALIZATION AND FUNCTION AND LONG-TERM POTENTIATION. Alzheimer's and Dementia, 2017, 13, P989.	0.8	1
41	P1-213: ELEVATED LEVELS OF MOSAIC ANEUPLOIDY IN HUNTINGTON'S DISEASE. Alzheimer's and Dementia, 2018, 14, P360.	0.8	1
42	P2-162: GM-CSF REVERSES MEMORY DEFICITS IN THE DP16 MOUSE MODEL OF DOWN SYNDROME. Alzheimer's and Dementia, 2018, 14, P730.	0.8	1
43	Transfection by Electroporation. Current Protocols in Molecular Biology, 1991, 14, 9.3.1-9.3.4.	2.9	1
44	Proteasome activity modulates amyloid toxicity. FEMS Yeast Research, 2022, 22, .	2.3	1
45	Kinesin light chain-1 variant E disrupts axonal transport and A β generation in Alzheimer's disease (comment on DOI 10.1002/bies.201400131). BioEssays, 2015, 37, 118-118.	2.5	0
46	P2-114: Increased Genomic Instability and Correlated Apoptosis are Associated with Cognitive Impairment in Neurodegenerative Diseases. Alzheimer's and Dementia, 2016, 12, P655.	0.8	0
47	[P2-140]: ABNORMAL CHROMOSOME COPY NUMBER AND ASSOCIATED NEURONAL CELL DEATH IN FRONTOTEMPORAL LOBAR DEGENERATION. Alzheimer's and Dementia, 2017, 13, P661.	0.8	0
48	[P2-143]: SCREENING FOR INHIBITORS OF APOE4-CATALYZED A β OLIGOMER/FILAMENT FORMATION: A NOVEL APPROACH TO ALZHEIMER'S DISEASE DRUG DISCOVERY. Alzheimer's and Dementia, 2017, 13, P662.	0.8	0
49	Small molecule inhibitors of apolipoprotein E4-catalyzed amyloid- β fibrillization as novel therapeutics for Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e043353.	0.8	0
50	Neuropathology and immune biomarker discovery in a rat model of Alzheimer's disease, TgF344-AD, with controlled cortical injury model of traumatic brain injury. Alzheimer's and Dementia, 2020, 16, e046103.	0.8	0
51	Double-blind placebo-controlled trial of the safety and efficacy of GM-CSF/sargramostim in subjects with mild-to-moderate Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e046497.	0.8	0
52	Role of mosaic aneuploidy in the development and progression of Huntington's disease. Alzheimer's and Dementia, 2020, 16, e047662.	0.8	0
53	Neuropsychiatric symptoms as a distinguishing factor between memory diagnoses. International Journal of Geriatric Psychiatry, 2020, 35, 1115-1122.	2.7	0
54	Age related changes in clonalities of T cell Age-related changes in clonalities of T cell receptor V β repertoire within CD8 subsets, but not CD4 in healthy individuals. FASEB Journal, 2008, 22, 375-375.	0.5	0

#	ARTICLE	IF	CITATIONS
55	Inflammation and innate immune system activation in neurodegeneration, Down syndrome, aging, and infection: Therapeutic target or partner?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
56	Granulocyte-macrophage colony-stimulating factor reverses Alzheimer's disease pathology in the tgf344-AD rat model.. <i>Alzheimer's and Dementia</i> , 2021, 17 Suppl 3, e056289.	0.8	0